Advanced Biomed CTO resigns; CFO joins board

Advanced Biomed Inc. reported leadership changes effective March 25, 2026.

Rhea-AI Filing Summary

Advanced Biomed Inc. reported leadership changes effective March 25, 2026. Steven I-Fang Cheng resigned as both a member of the Board of Directors and as Chief Technology Officer. The company stated that his resignation was not due to any disagreement over operations, policies, or practices.

On the same date, the Board, following a recommendation from the Nominating Committee, appointed Chief Financial Officer Mingze Yin as a director. The company disclosed that Mr. Yin has no family relationships with other leaders, no special arrangements leading to his appointment, and no related-party transactions requiring disclosure.

Insights

Corporate governance analyst

Advanced Biomed reshuffles leadership with CTO exit and CFO board appointment.

The company announced that Steven I-Fang Cheng resigned as director and Chief Technology Officer effective March 25, 2026. The company explicitly noted his decision was not due to any disagreement on operations, policies, or practices, which reduces concern about internal conflict.

On the same date, Chief Financial Officer Mingze Yin joined the Board after a Nominating Committee recommendation. The disclosure emphasizes there are no family relationships, appointment arrangements, or related-party transactions under Item 404(a) of Regulation S-K, suggesting a straightforward governance move rather than a complex insider transaction.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

CTO resignation effective date: March 25, 2026 Director appointment date: March 25, 2026 Form type: Form 8-K +1 more

4 metrics

CTO resignation effective date March 25, 2026 Effective date of Steven I-Fang Cheng’s resignation as director and CTO

Director appointment date March 25, 2026 Effective date of CFO Mingze Yin’s appointment to the Board

Form type Form 8-K Current report under the Securities Exchange Act of 1934

Company jurisdiction Nevada State of incorporation for Advanced Biomed Inc.

Key Terms

Chief Technology Officer, Nominating Committee, Item 404(a) of Regulation S-K, Emerging growth company, +1 more

5 terms

Chief Technology Officer financial

"resignation as a member of the Board of Directors and as Chief Technology Officer of the Company"

The chief technology officer is the senior executive who sets a company's technology vision and oversees development, engineering, and technical operations—think of them as the lead architect and head mechanic who decides what tools the business builds and how they run. Their choices affect product direction, cost structure, cybersecurity and scalability, so investors watch the CTO to gauge a company’s ability to innovate, compete and manage technical risk.

Nominating Committee financial

"upon the recommendation of the Nominating Committee, the Board of Directors appointed Mingze Yin"

A nominating committee is a small group of company directors tasked with finding, evaluating and recommending people to serve on the board. Think of it as a hiring panel that chooses the team responsible for guiding the business and holding management accountable. Investors care because the committee’s choices shape the board’s experience, independence and judgment, which directly affect strategy, oversight, leadership succession and the protection of shareholder interests.

Item 404(a) of Regulation S-K regulatory

"There are no transactions in which Mr. Yin has an interest requiring disclosure under Item 404(a) of Regulation S-K"

Emerging growth company regulatory

"Emerging growth company Securities registered pursuant to Section 12(b) of the Act"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Board of Directors financial

"resignation as a member of the Board of Directors and as Chief Technology Officer of the Company"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Advanced Biomed Inc. (ADVB) disclose?

Advanced Biomed Inc. disclosed that Steven I-Fang Cheng resigned as both a director and Chief Technology Officer effective March 25, 2026. The company also appointed Chief Financial Officer Mingze Yin to its Board of Directors on the same date, following a recommendation from the Nominating Committee.

Why did Advanced Biomed’s CTO and director Steven I-Fang Cheng resign?

The company stated that Steven I-Fang Cheng’s resignation as director and Chief Technology Officer was not due to any disagreement with the company. This includes no disagreement regarding its operations, policies, or practices, indicating the departure was not reported as stemming from internal disputes.

Who was appointed to the Advanced Biomed (ADVB) Board of Directors?

Advanced Biomed appointed its Chief Financial Officer, Mingze Yin, as a director effective March 25, 2026. The Board acted upon a recommendation from the Nominating Committee, and the company highlighted that he has no family relationships or special arrangements tied to this appointment.

Does Advanced Biomed report any related-party transactions involving director Mingze Yin?

The company reported there are no transactions involving director and CFO Mingze Yin that require disclosure under Item 404(a) of Regulation S-K. This means no qualifying related-party dealings were identified in connection with his role or appointment to the Board of Directors.

Are there any family relationships linked to Advanced Biomed’s new director?

Advanced Biomed disclosed that new director and Chief Financial Officer Mingze Yin has no family relationships with any director or executive officer. The filing also notes there were no arrangements or understandings with other persons that led to his appointment as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 05:32 PM EDT Learn about SEC filing dates

false 00000 0001941029 0001941029 2026-03-25 2026-03-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

March 25, 2026

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

Nevada		001-42548		87-2177170
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification Number)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ADVB		The Nasdaq Stock Market LLC

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director and Chief Technology Officer.

On March 25, 2026, Steven I-Fang Cheng notified Advanced Biomed Inc. (the “Company”) of his resignation as a member of the Board of Directors and as Chief Technology Officer of the Company, effective as of March 25, 2026. Mr. Cheng’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Appointment of Director.

On March 25, 2026, upon the recommendation of the Nominating Committee, the Board of Directors appointed Mingze Yin, the Chief Financial Officer of the Company, as a director of the Company, effective as of March 25, 2026.

There are no family relationships between Mr. Yin and any director or executive officer of the Company. There are no arrangements or understandings between Mr. Yin and any other person pursuant to which he was appointed as a director. There are no transactions in which Mr. Yin has an interest requiring disclosure under Item 404(a) of Regulation S-K.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Advanced Biomed Inc.
Date: March 30, 2026	By:	/s/ Yi Lu
		Yi Lu
		Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB